# US 2025/0360217 A1 · Hyaluronic acid derivative pharmaceutical composition and method of producing pharmaceutical composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0360217 A1
- Document ID: US20250360217A1
- Status: Published application
- Kind: A1
- Application number: 18/995,468
- Filed: 2023-07-20
- Published: 2025-11-27
- Earliest claimed: 2022-07-20
- Assignees: Asahi Kasei Kabushiki Kaisha
- Applicants: Asahi Kasei Kabushiki Kaisha
- Inventors: Kohei YABUUCHI; Takashi NAKAI
- Web page: https://patentgrep.com/patent/US20250360217A1

## CPC

- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/728: Hyaluronic acid
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/13: Cyclosporins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C08B 37/0072: {Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates}
- C08L 5/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

A hyaluronic acid derivative pharmaceutical composition includes a hyaluronic acid derivative (A) into which a hydrophobic group has been introduced, an association promoter (B), and an active ingredient (C). It is preferable that the association promoter (B) has at least four or more ether structures (R—O—R) and 4 or more carbon atoms.

## Claims

### Claim 1

A hyaluronic acid derivative pharmaceutical composition comprising:
a hyaluronic acid derivative (A) into which a hydrophobic group has been introduced;
an association promoter (B); and
an active ingredient (C).

### Claim 2 (depends on 1)

The hyaluronic acid derivative pharmaceutical composition according to claim 1,
wherein the association promoter (B) has at least four or more ether structures (R—O—R) and has 4 or more carbon atoms.

### Claim 3 (depends on 1)

The hyaluronic acid derivative pharmaceutical composition according to claim 1,
wherein the association promoter (B) is one or more selected from the group consisting of polysorbate 80, polysorbate 20, poloxamer, oxyethylene castor oil, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 4000, fatty acid sorbitan ester, tocopheryl polyethylene glycol succinate, and polyvinyl alcohol.

### Claim 4 (depends on 1)

The hyaluronic acid derivative pharmaceutical composition according to claim 1,
wherein a precipitate is generated at a physiological saline concentration.

### Claim 5 (depends on 1)

The hyaluronic acid derivative pharmaceutical composition according to claim 1,
wherein the active ingredient (C) is at least one selected from a protein or a poorly water-soluble drug.

### Claim 6 (depends on 5)

The hyaluronic acid derivative pharmaceutical composition according to claim 5,
wherein the poorly water-soluble drug has a solubility of 1 mg/mL or less in water.

### Claim 7 (depends on 5)

The hyaluronic acid derivative pharmaceutical composition according to claim 5,
wherein the poorly water-soluble drug has a molecular weight of 200 or greater.

### Claim 8 (depends on 5)

The hyaluronic acid derivative pharmaceutical composition according to claim 5,
wherein the poorly water-soluble drug is a poorly water-soluble peptide.

### Claim 9 (depends on 8)

The hyaluronic acid derivative pharmaceutical composition according to claim 8,
wherein in the poorly water-soluble peptide, at least one nitrogen atom constituting an amide bond has a methyl group.

### Claim 10 (depends on 8)

The hyaluronic acid derivative pharmaceutical composition according to claim 8,
wherein the poorly water-soluble peptide includes at least one or more selected from the group consisting of a cyclic peptide and a long-chain peptide.

### Claim 11 (depends on 8)

The hyaluronic acid derivative pharmaceutical composition according to claim 8,
wherein the poorly water-soluble peptide is a cyclic peptide.

### Claim 12 (depends on 1)

The hyaluronic acid derivative pharmaceutical composition according to claim 1,
wherein an amount of the active ingredient (C) is 10 parts by mass or greater and 100 parts by mass or less with respect to 100 parts by mass of the hyaluronic acid derivative (A) into which the hydrophobic group has been introduced.

### Claim 13 (depends on 1)

The hyaluronic acid derivative pharmaceutical composition according to claim 1,
wherein the hyaluronic acid derivative (A) into which the hydrophobic group has been introduced has one or more repeating units represented by General Formula (I),
(in the formula, R1, R2, R3, and R4 each independently represent a group selected from the group consisting of a hydrogen atom, C1-6 alkyl, formyl, and C1-6 alkylcarbonyl,
Z represents a direct bond or a peptide linker formed of 2 or more and 30 or less of any amino acid residues,
X1 represents a group selected from the group consisting of a group represented by —NRb—R, —NRb—COO—R, —NRb—CO—R, —NRb—CO—NRc—R, —COO—R, —O—COO—R, —S—R, —CO—Ya—S—R, —O—CO—Yb—S—R, —NRb—CO—Yb—S—R, and —S—S—R,
Ra, Rb, and Rc each independently represent a group selected from the group consisting of a hydrogen atom, C1-20 alkyl, amino C2-20 alkyl, and hydroxy C2-20 alkyl,
a group selected from the group consisting of —O— and —NRf— may be inserted into an alkyl moiety of each of Ra, Rb, and Rc,
Rf represents a group selected from the group consisting of a hydrogen atom, C1-12 alkyl, amino C2-12 alkyl, and hydroxy C2-12 alkyl,
a group selected from the group consisting of —O— and —NH— may be inserted into an alkyl moiety of R,
R represents a steryl group,
Y represents C2-30 alkylene or —(CH2CH2O)m—CH2CH2—,
where a group selected from the group consisting of —O—, —NRg—, and —S—S— may be inserted into alkylene of Y,
Rg represents a group selected from the group consisting of a hydrogen atom, C1-20 alkyl, amino C2-20 alkyl, and hydroxy C2-20 alkyl,
a group selected from the group consisting of —O— and —NH— may be inserted into an alkyl moiety of Rg,
Ya represents C1-5 alkylene,
Yb represents C2-8 alkylene or C2-8 alkenylene, and
m represents an integer of 1 or greater and 100 or less).

### Claim 14 (depends on 13)

The hyaluronic acid derivative pharmaceutical composition according to claim 13,
wherein the steryl group is a cholesteryl group.

### Claim 15 (depends on 13)

The hyaluronic acid derivative pharmaceutical composition according to claim 13,
wherein an introduction rate of the steryl group into the hyaluronic acid derivative is 7% or greater and less than 35%.

### Claim 16 (depends on 1)

The hyaluronic acid derivative pharmaceutical composition according to claim 1,
wherein in the hyaluronic acid derivative pharmaceutical composition, no precipitate is visually observed.

### Claim 17 (depends on 1)

The hyaluronic acid derivative pharmaceutical composition according to claim 1,
wherein the hyaluronic acid derivative pharmaceutical composition is filter-sterilizable.

### Claim 18

A method of producing a hyaluronic acid derivative pharmaceutical composition including a hyaluronic acid derivative (A) into which a hydrophobic group has been introduced, an association promoter (B), and an active ingredient (C), the method comprising:
mixing the hyaluronic acid derivative (A) into which a hydrophobic group has been introduced with the association promoter (B) to obtain an association promoter-containing hyaluronic acid derivative aqueous solution; and
mixing the active ingredient (C) with the association promoter-containing hyaluronic acid derivative aqueous solution.

### Claim 19

A method of producing a hyaluronic acid derivative pharmaceutical composition including a hyaluronic acid derivative (A) into which a hydrophobic group has been introduced, an association promoter (B), and an active ingredient (C), the method comprising:
dispersing the active ingredient (C) in the association promoter (B) to obtain a dispersion liquid (I);
preparing a hyaluronic acid derivative aqueous solution or an association promoter-containing hyaluronic acid aqueous solution to obtain an aqueous solution (II); and
mixing the dispersion liquid (I) with the aqueous solution (II).

### Claim 20 (depends on 18)

The method of producing a hyaluronic acid derivative pharmaceutical composition according to claim 18,
wherein the method does not include removing an organic solvent.

### Claim at position 21

21-40. (canceled)
